Loading...
XKRX
003850
Market cap534mUSD
Jun 05, Last price  
8,650.00KRW
1D
0.00%
1Q
-12.00%
Jan 2017
-6.11%
Name

Boryung Corp

Chart & Performance

D1W1MN
XKRX:003850 chart
No data to show
P/E
10.43
P/S
0.71
EPS
829.33
Div Yield, %
—
Shrs. gr., 5y
3.09%
Rev. gr., 5y
14.17%
Revenues
1.02t
+18.32%
197,500,614,000223,259,471,000267,844,294,000300,958,914,000308,005,546,820312,075,037,440327,278,733,560359,490,950,700401,350,239,840409,140,006,900422,721,051,680460,401,670,470524,268,670,100561,866,592,450627,279,390,050760,475,844,690859,625,585,7601,017,106,670,440
Net income
69.63b
+73.20%
8,418,563,0005,205,610,0005,182,161,00013,648,778,0006,178,116,7309,401,047,02014,126,625,32021,590,563,67020,301,086,0305,614,105,35056,698,581,46020,306,902,10032,221,802,69026,856,199,16043,044,274,38041,894,431,74040,202,797,52069,633,253,500
CFO
80.56b
+90.79%
20,223,089,00013,079,677,0003,593,431,00022,939,541,0009,185,915,50018,378,731,06028,527,119,2609,340,832,30017,114,340,7209,363,178,140-24,263,565,30038,913,967,70046,998,848,99044,740,976,18060,167,363,91027,814,064,61042,223,902,69080,557,153,480
Dividend
Dec 27, 2023100 KRW/sh
Earnings
Jul 29, 2025

Profile

Boryung Corporation produces and sells pharmaceutical products in South Korea. The company offers cardiovascular products, anticancer products, gastrointestinal products, and API's. It also exports its products to approximately 50 countries on 6 continents, including Japan, China, the Southeast Asia, the Middle East, Europe, South America, and Africa. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is based in Seoul, South Korea.
URL
https://www.boryung.co.kr/en/
IPO date
Oct 24, 1988
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,017,106,670
18.32%
859,625,586
13.04%
760,475,845
21.23%
Cost of revenue
804,295,815
645,538,831
587,011,212
Unusual Expense (Income)
NOPBT
212,810,856
214,086,754
173,464,632
NOPBT Margin
20.92%
24.90%
22.81%
Operating Taxes
(6,676,375)
16,092,403
16,933,656
Tax Rate
7.52%
9.76%
NOPAT
219,487,231
197,994,351
156,530,976
Net income
69,633,254
73.20%
40,202,798
-4.04%
41,894,432
-2.67%
Dividends
(6,766,571)
(6,586,571)
(6,588,571)
Dividend yield
1.00%
0.84%
1.10%
Proceeds from repurchase of equity
174,999,992
(185,671)
BB yield
-25.82%
0.03%
Debt
Debt current
42,269,199
51,633,442
113,697,450
Long-term debt
130,592,681
154,479,135
95,679,915
Deferred revenue
(9,744,416)
Other long-term liabilities
13,906,582
12,593,579
3,934,012
Net debt
(158,141,732)
51,420,347
64,056,406
Cash flow
Cash from operating activities
80,557,153
42,223,903
27,814,065
CAPEX
(12,825,121)
(15,020,194)
(122,995,419)
Cash from investing activities
(40,842,817)
(29,161,099)
(147,650,952)
Cash from financing activities
128,377,771
(12,645,813)
(14,649,025)
FCF
189,990,838
138,376,535
120,526,923
Balance
Cash
191,849,193
20,054,672
17,916,970
Long term investments
139,154,419
134,637,559
127,403,989
Excess cash
280,148,279
111,710,952
107,297,166
Stockholders' equity
510,034,186
377,430,344
483,869,021
Invested Capital
686,868,559
653,848,065
595,099,306
ROIC
32.74%
31.71%
28.44%
ROCE
22.01%
27.95%
24.36%
EV
Common stock shares outstanding
65,866
65,931
66,126
Price
10,290.00
-13.46%
11,890.00
31.24%
9,060.00
-37.95%
Market cap
677,758,156
-13.54%
783,921,659
30.85%
599,103,680
-34.90%
EV
519,616,424
835,844,951
663,659,251
EBITDA
255,660,000
258,473,824
211,108,822
EV/EBITDA
2.03
3.23
3.14
Interest
8,997,673
9,549,147
6,127,446
Interest/NOPBT
4.23%
4.46%
3.53%